格隆汇1月8日丨仙琚制药(002332.SZ)公布，近日收到国家药品监督管理局核准签发的关于倍他米松磷 酸钠注射液的《药品注册证书》（证书编号：2026S00006），公司倍他米松磷酸钠注射液被批准注 册。倍他米松磷酸钠注射液，规格1ml：4mg（按C₂₂H₂₉FO₅计），参比制剂为欧盟上市的倍他米松磷酸 钠注射液，商品名Celestone®。倍他米松磷酸钠注射液最早由先灵葆雅公司开发,持证商最终变更为 Organon公司。倍他米松磷酸钠注射液主要用于需要使用糖皮质激素治疗的疾病。Organon公司的倍他米 松磷酸钠注射液已在比利时、瑞典、荷兰、德国、法国、波兰等多个国家上市。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Betamethasone Sodium Phosphate Injection, which is expected to enhance its product line and competitiveness [1] Group 1: Product Approval - The approved drug is Betamethasone Sodium Phosphate Injection, with a specification of 1ml: 4mg (calculated as C₂₂H₂₉FO₅) [1] - The registration classification of the drug is categorized as Class 3 chemical drugs [1] Group 2: Market Impact - The drug is primarily used for the treatment of diseases related to glucocorticoids, and the original drug has been marketed in multiple countries [1] - The approval is seen as beneficial for the company in terms of expanding its product offerings and improving its competitive position in the market [1] Group 3: Uncertainties - The research, production, and sales of the drug are subject to uncertainties influenced by policies and market factors [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局核准签发的关于倍他米松磷酸钠注射液的《药品注册证书》（证书编号： 2026S00006），公司倍他米松磷酸钠注射液被批准注册。现将相关情况公告如下： 申请内容：境内生产药品注册上市许可。 证券代码：002332 证券简称：仙琚制药 公告编号：2026-001 浙江仙琚制药股份有限公司 关于取得倍他米松磷酸钠注射液境内生产药品注册证书的公告 由于药品研发、生产和销售容易受到国家政策、市场环境等因素影响，具有 较大不确定性，敬请广大投资者注意投资风险。 特此公告。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他相关情况 倍他米松磷酸钠注射液，规格1ml：4mg（按C₂₂H₂₉FO₅计），参比制剂为欧盟 上市的倍他米松磷酸钠注射液，商品名Celestone®。倍他米松磷酸钠注射液最早 由先灵葆雅公司开发,持证商最终变更为Organon公司。倍他米松磷酸钠注射 ...

Core Viewpoint - The fourth batch of encouraged generic drug catalog has been released, including 21 drug varieties and 47 specifications, addressing the shortage of clinical supplies and the need for domestic drug development [1][2]. Group 1: Drug Catalog Expansion - The fourth batch of the encouraged generic drug catalog includes 21 drug varieties, bringing the total to 110 since the first three batches were released in 2019, 2021, and 2023 [1]. - The new catalog focuses on major diseases such as cancer and rare diseases, as well as chronic diseases, mental health issues, and reproductive health, reflecting the changing disease burden and clinical needs due to demographic trends [1][2]. Group 2: Selection Criteria and Clinical Needs - The selection of drugs for the fourth batch was guided by patient treatment needs, considering clinical guidelines and domestic research status, with input from various experts [2]. - New drugs with novel targets and mechanisms, such as those for chronic kidney disease-related itching, have been included, along with radioactive drugs not yet available in the domestic market [2]. Group 3: Specific Drug Examples - Suvorexant, a new drug for insomnia, has been included in the catalog to address the high prevalence of insomnia symptoms among the Chinese population, with 59% of surveyed residents reporting such issues [3]. - The catalog also includes drugs for rare diseases, such as Deflazacort for Duchenne muscular dystrophy, and aims to enhance reproductive health with low-adverse-effect products [3][4]. Group 4: Challenges in Generic Drug Development - Despite being a major player in generic drugs, China faces challenges in becoming a stronghold in this sector due to technical barriers and insufficient incentives for research and development [5][6]. - As of September last year, only 40 out of 89 drugs listed in the previous three catalogs had been approved for market entry, indicating a significant gap in the availability of generic drugs [5]. Group 5: Future Support and Policy Directions - The government aims to enhance support for the encouraged generic drug catalog through improved clinical trials, key technology research, and expedited review processes [6]. - Policies are being developed to provide market exclusivity for certain categories of drugs, including those for rare diseases and children's medications, to stimulate research and development [6].

Core Insights - The article discusses the competitive landscape of the hair medical industry in China, highlighting key players and market dynamics [1][5]. Group 1: Competitive Landscape - The Chinese hair medical industry features various competitive factions, with companies like Yonghe Medical, Damaik, and Qingyi focusing on hair transplant medical services, while SanSheng Pharmaceutical, Zhendong Pharmaceutical, and Xianju Pharmaceutical are involved in medical nurturing services [1]. - In the hair transplant sector, the first tier consists of leading national chain brands such as Yonghe Medical, Bilian Sheng, and Damaik, which collectively hold a significant market share and possess nationwide direct chain layouts, mature technology systems, and strong brand recognition [1]. Group 2: Hair Growth Pharmaceuticals - In the hair growth pharmaceuticals market, the first tier includes SanSheng Pharmaceutical, Zhendong Pharmaceutical, and Merck, with the former two holding major shares in the minoxidil market, while Merck is recognized as the original manufacturer of finasteride [5]. - The second tier comprises Xianju Pharmaceutical, Kang En Bei, and Xiamen Meishang Pharmaceutical, which have accelerated the launch of minoxidil and finasteride products in recent years, gaining notable market recognition [5]. Group 3: Sales Performance - In the online pharmacy sector, Zhejiang SanSheng's minoxidil tincture product achieved sales exceeding 1 billion yuan, while Zhendong Anxin's minoxidil lotion surpassed 300 million yuan in sales, and SanSheng's minoxidil foam also exceeded 100 million yuan [9]. - In the offline market during the first quarter of 2025, Zhejiang SanSheng's minoxidil tincture and Zhendong Anxin's minoxidil lotion both recorded sales above 20 million yuan, with market shares of 50.61% and 38.82%, respectively [10]. - The sales ranking for minoxidil products shows Zhejiang SanSheng's minoxidil tincture leading with over 34 million yuan in sales (50.61% market share), followed by Zhendong Anxin's minoxidil lotion with over 26 million yuan (38.82% market share) [11].

证券日报网讯12月26日，仙琚制药（002332）在互动平台回答投资者提问时表示，股价波动受宏观经 济、行业环境、市场情绪、公司发展阶段等多种因素影响。 ...

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the sector [1]. Industry Summary - As of October 2025, the production of chemical pharmaceutical raw materials in China reached 313,000 tons, showing a year-on-year decrease of 1.6% [1]. - From January to October 2025, the cumulative production of chemical pharmaceutical raw materials was 3,049,000 tons, reflecting a cumulative growth of 1.3% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1].

Group 1 - The core viewpoint of the news is that Xianju Pharmaceutical has experienced fluctuations in financing and stock performance, with significant changes in both revenue and net profit year-on-year [1][2]. - As of December 19, Xianju Pharmaceutical's stock price increased by 0.99%, with a trading volume of 79.39 million yuan. The financing buy-in amount was 5.69 million yuan, while the financing repayment was 12.40 million yuan, resulting in a net financing buy-in of -6.71 million yuan [1]. - The total balance of margin trading for Xianju Pharmaceutical reached 494 million yuan, with the financing balance accounting for 5.41% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of November 30, the number of shareholders for Xianju Pharmaceutical was 50,000, a decrease of 1.96% from the previous period, while the average circulating shares per person increased by 2.00% to 19,691 shares [2]. - For the period from January to September 2025, Xianju Pharmaceutical reported an operating income of 2.826 billion yuan, a year-on-year decrease of 12.71%, and a net profit attributable to the parent company of 407 million yuan, down 23.29% year-on-year [2]. - Since its A-share listing, Xianju Pharmaceutical has distributed a total of 2.031 billion yuan in dividends, with 989 million yuan distributed over the past three years [3].

2025年1至6月份，仙琚制药的营业收入构成为：医药占比99.34%，其他业务占比0.66%。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ 每经AI快讯，仙琚制药（SZ 002332，收盘价：9.19元）12月19日晚间发布公告称，公司第九届2025年 第三次董事会临时会议于2025年12月19日在公司会议室召开。会议审议了《关于选举公司第九届董事会 董事长及执行公司事务的董事的议案》等文件。 （记者 曾健辉） 截至发稿，仙琚制药市值为91亿元。 ...

股票代码：002332 股票简称：仙琚制药 公告编号：2025-058 浙江仙琚制药股份有限公司 关于选举第九届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司第八届董事会任期即将届满。根据《公司法》《公 司章程》等有关规定，公司于2025年12月19日召开职工代表大会，选举第九届董事 会职工代表董事。经与会职工代表认真讨论，选举戴静女士为公司第九届董事会职 工代表董事，并与公司2025年第三次临时股东大会选举产生的八名董事共同组成公 司第九届董事会，任期三年。 特此公告。 浙江仙琚制药股份有限公司 董事会 2025 年 12 月 20 日 戴静：女，1982年12月出生，中国国籍，无境外永久居留权，博士，中共党员， 高级工程师。2011年9月入职浙江仙琚制药股份有限公司，历任实验员、研究院主任、 研究院副院长，2012年至2013赴美国葛兰素史克开展博士后研究工作，现任公司原 料药研究院院长、仙琚（嘉兴）医药科技有限公司执行董事、总经理，公司职工代 表董事。未持有本公司股份，与持有公司5%以上股份的股东、实际 ...